More Articles Back to Article
Phase I trial results for Jannsen's Zika vaccine are out
Data from an early-stage trial testing the Zika vaccine developed by Johnson & Johnson's unit Janssen showed it induced immunity against the virus for up to 12 months in 80% of recipients, based on results reported in the journal Annals of Internal Medicine. A midstage trial is currently ongoing, the manufacturer said. United Press International (2/15)
Read full article now.
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!